NCT05782322

Effects and Mechanisms of RAS Training on Upper-limb Movements in PD Patients

Not yet recruiting NA Last updated 10 April 2025

What this trial tests

NA trial testing Upper-limb training involving RAS in Acoustic Stimulation in 72 participants. Not yet recruiting.

Timeline

1 May 2025

Primary endpoint
31 March 2026

31 March 2026

Quick facts

Lead sponsor	The Hong Kong Polytechnic University
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	72
Start date	1 May 2025
Primary completion	31 March 2026
Estimated completion	31 March 2026

Drugs / interventions tested

• Upper-limb training involving RAS
• Upper-limb training without the aid of RAS

Conditions studied

• Acoustic Stimulation — all drugs for Acoustic Stimulation →
• Parkinson Disease — all drugs for Parkinson Disease →
• Electroencephalography — all drugs for Electroencephalography →

Sponsor

The Hong Kong Polytechnic University

Who can join

Adults 18 to 85, any sex, with Acoustic Stimulation or Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Introduction Bradykinesia (i.e., slow movements) is one of the most prominent symptoms of Parkinson's disease (PD) and has a negative impact on quality of life. Rhythmic auditory stimulation (RAS), a widely used and promising treatment technique, has been shown to effectively improve gait speed in PD patients. However, only few studies have explored effects and neural mechanisms of RAS on upper-limb movements. We will conduct two studies to investigate effects and mechanisms of RAS on upper-limb movements in PD patients. The purpose of this study is to examine effects and neural mechanisms of upper-limb movement training involving RAS in PD patients.

Methods This study will recruit patients with PD and healthy controls. This study will randomly assign PD patients into two groups: the PD-RAS group and the PD-noRAS group, and healthy controls into the HC-RAS group and the HC-noRAS group. A 7-day upper-limb training involving RAS (for the PD-RAS group and the HC-RAS group) or without RAS (for the PD-noRAS group and the HC-noRAS group) will be provided. EEG and behavioral assessments will be conducted before and after the first day of training, and after the seven-day training program. Two-way repeated measures analysis of variance will be performed to investigate the group and time effects on upper-limb function and neural activity.

Study significance The training program will serve as a reference for clinical practitioners who are interested in using RAS in clinical training for PD patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.